2 results
Approved WMORecruiting
To determine non inferiority of two doses of BI 10773 (10 mg/daily and 25 mg/daily) compared to placebo with respect to first occurrence of any of the adjudicated components of the primary composite Major Adverse Cardiovascular Event endpoint (…
Approved WMOCompleted
Objective: The primary objective of the study is to determine whether the intracervical installation of vasopressin reduces the incidence and severity of gas embolism as detected by trans oesophageal echocardiography (TOE).The secondary objective is…